IR Licensing and Partnerships

Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class of therapies capable of targeting historically “undruggable” intracellular proteins.

Rigel Pharmaceuticals has licensed Veppanu, positioning the company to expand into protein degradation-based oncology treatments for ESR1-mutated metastatic breast cancer.

Boehringer Ingelheim has licensed a preclinical antibody program from Immunitas Therapeutics for inflammatory diseases, signaling continued demand for earlier-stage immunology assets.

In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst Pharmaceuticals, Incyte presents 24-week results from the Phase III TRuE-AD4 trial of Opzelura, and Pharmaceutical Executive speaks with Charlie Lyon of the API Innovation Center on what the conversation about bringing pharmaceutical manufacturing back to the United States is still missing.

Angelini Pharma acquires Catalyst Pharmaceuticals in a $4.1 billion deal, expanding into the U.S. rare disease market and adding a portfolio of approved neuromuscular and neurological therapies.

Madrigal and Bayer strike billion-dollar deals to expand pipelines, with Madrigal licensing a PNPLA3-targeting siRNA for MASH and Bayer acquiring Perfuse Therapeutics to strengthen its ophthalmology portfolio.

UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager cizutamig to expand its immunology pipeline.

Teva will acquire Emalex to add ecopipam, a late-stage pediatric Tourette syndrome candidate, ahead of a planned 2026 filing.

Sun Pharma is set to acquire Organon in a $11.75 billion deal, while IMG Pharma enters a definitive agreement to purchase Matsumoto, signaling continued global consolidation and portfolio expansion across the pharmaceutical industry.

Pfizer’s broad pipeline and recent acquisitions have yet to translate into a coherent market narrative, contributing to investor uncertainty during a critical period of strategic transition.

Eli Lilly’s acquisition of Kelonia Therapeutics signals a potential shift in the cell therapy landscape, as in vivo approaches aim to overcome the cost, complexity, and access limitations of traditional CAR-T treatments.

Obsidian Therapeutics and Galera are merging to form a Nasdaq-listed cell therapy company backed by a $350 million private placement, aiming to advance OBX-115, a next-generation TIL therapy.

AbbVie entered a global licensing deal with Haisco worth up to $715 million to expand its pain pipeline with several assets.

C4 Therapeutics and Roche expanded their partnership to develop next-generation degrader-antibody conjugates, a novel oncology approach designed to improve the precision and therapeutic index of traditional antibody-drug conjugates.

Gilead Sciences’ acquisition of Tubulis underscores the intensifying industry focus on antibody-drug conjugates as a key frontier in oncology treatment.

Neurocrine Biosciences’ planned $2.9 billion acquisition of Soleno Therapeutics includes the addition of Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome.

Shionogi completed its $2.5 billion acquisition of global rights to Radicava from Tanabe Pharma, adding one of the few approved treatments for ALS to its portfolio .

Biogen acquires Apellis Pharmaceuticals in a deal that brings two marketed complement therapies into its portfolio, strengthening its position in immunology.

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery.

Eli Lilly agreed to acquire Centessa Pharmaceuticals for approximately $7.8 billion, expanding its neuroscience pipeline.

The agreement grants Lilly an exclusive worldwide license to a portfolio of preclinical oral therapeutics.

Novartis and Otsuka Pharmaceutical are advancing deals to expand pipelines in allergy and psychiatry, with Novartis targeting next-generation anti-IgE therapy and Otsuka betting on a rapid-acting PTSD treatment.

Merck is acquiring Terns Pharmaceuticals for $6.7 billion to bolster its oncology pipeline, while Shionogi is set to purchase 50% of Apnimed's ownership of SASS.

Merck agrees to multi-year research collaboration with Quotient Therapeutics in a deal worth up to $2.2 billion to use somatic genomics and AI-driven analytics to identify new drug targets for inflammatory bowel disease.

The deal adds OM336, a BCMAxCD3 bispecific T cell engager showing early efficacy in rare antibody-mediated autoimmune diseases, to Gilead's pipeline.